Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Sorafenib + Gilteritinib
- Development stage
- Unknown
- Lead developer
- Bayer
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Sorafenib + Gilteritinib refers to the use of the tyrosine kinase inhibitors sorafenib and gilteritinib as maintenance therapy options for patients with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS) following allogeneic hematopoietic stem cell transplantation (allo-HSCT). This regimen is part of a genetics-guided umbrella study (NCT05343949) at Ruijin Hospital, where patients with FLT3 mutations receive one of these agents to prevent post-transplant relapse. Sorafenib is a first-generation multi-kinase inhibitor targeting the Raf/MEK/ERK pathway, VEGFR, and PDGFR, whereas gilteritinib is a second-generation inhibitor with high selectivity for FLT3 (both ITD and TKD mutations) and AXL. The treatment aims to provide targeted suppression of leukemic clones during the high-risk post-transplant period.
- Brand names
- NexavarXospata
- Other names
- giritinibSorafenib tosylateGilteritinib fumarate
02
Targets
AXL (AXL receptor tyrosine kinase)BRAF (B-Raf proto-oncogene, serine/threonine kinase)VEGFR3 (Vascular endothelial growth factor receptor 3)FGFR1 (Fibroblast growth factor receptor 1)KIT (c-KIT proto-oncogene receptor tyrosine kinase)RK (Ribokinase)RAF1 (c-Raf-1 (Y340D/Y341D))PDGFRB (Platelet-derived growth factor receptor beta)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR2 (Vascular endothelial growth factor receptor 2)RET (Rearranged during transfection receptor tyrosine kinase)FLT3 (Fms related receptor tyrosine kinase 3)
Beyond the preview
Go deeper on Sorafenib + Gilteritinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Sorafenib + Gilteritinib.